Belantamab Mafodotin: First Approval
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Belantamab mafodotin (BLENREP ™ ; belantamab mafodotin-blmf) is a first-in-class monoclonal antibody-drug conjugate (ADC) that has been developed for the treatment of multiple myeloma by GlaxoSmithKline. The ADC comprises an antibody targeting B-cell maturation antigen (BCMA) conjugated to the microtubule inhibitor monomethyl auristatin F (MMAF). The antibody moiety binds to BCMA on the tumour cell surface, delivering the cytotoxic microtubule inhibitor MMAF to the therapeutic target. Based on preliminary results from the multinational DREAMM-2 trial, belantamab mafodotin was approved in early August 2020 in the USA for the treatment of relapsed or refractory multiple myeloma in adult patients who have received at least four prior therapies, including an anti CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent. The ADC was also approved in the EU for this indication in late August 2020. This article summarizes the milestones in the development of belantamab mafodotin leading to this first approval.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Blenrep (belantamab mafodotin-blmf) is a groundbreaking ADC developed by GSK for the treatment of RRMM. It is the first ADC approved by the FDA and EMA for this indication [186].”
From Multiple myeloma: signaling pathways and targeted therapy (2024) · cites this paper as [186]
Citations
Cites
Lonial, S., Lee, H. C., Badros, A., Trudel, S., Nooka, A. K., Chari, A., Abdallah, A.-O., Callander, N., Lendvai, N., Sborov, D., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30788-0 · Cited by 812 · cited 4×
“4 mg/kg (n = 99) once every 3 weeks until disease progression or unacceptable toxicity [11].”
BackgroundInfluentialTai, Y.-T., Mayes, P. A., Acharya, C., Zhong, M. Y., Cea, M., Cagnetta, A., Craigen, J., Yates, J., Gliddon, L., Fieles, W., et al. (2014) · Blood · doi:10.1182/blood-2013-10-535088 · Cited by 484
Trudel, S., Lendvai, N., Popat, R., Voorhees, P. M., Reeves, B., Libby, E. N., Richardson, P. G., Hoos, A., Gupta, I., Bragulat, V., et al. (2019) · Blood Cancer Journal · doi:10.1038/s41408-019-0196-6 · Cited by 213
Lonial, S., Lee, H. C., Badros, A., Trudel, S., Nooka, A. K., Chari, A., Abdallah, A.-O. A., Callander, N. S., Sborov, D. W., Suvannasankha, A., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.8536 · Cited by 27 · cited 3×
“2.3.1.1 Phase II Single agent therapy with belantamab mafodotin had promising activity in patients with relapsed or refractory multiple myeloma in the phase II DREAMM-2 study (NCT03525678) [11, 12].”
BackgroundInfluentialUsmani, S. Z., Terpos, E., Janowski, W., Quach, H., West, S., Williams, D., Dettman, E. J., Ferron‐Brady, G., Luptakova, K., & Gupta, I. V. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.tps8556 · Cited by 18 · cited 1×
“The global phase III DREAMM-9 study (NCT04091126) is being conducted to evaluate the efficacy of belantamab mafodotin in combination with bortezomib, lenalidomide and dexamethasone compared to bortezomib, lenalidomide and dexamethasone alone in patients with transplant-ineligible newly diagnosed multiple myeloma [19].”
BackgroundRichardson, P. G. G., Biswas, S., Holkova, B., Jackson, N., Netherway, T., Paul, S., Ferron‐Brady, G., Yeakey, A. M., Shelton, C., Oca, R. M. D., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.tps8552 · Cited by 7 · cited 1×
“antibody GSK3359609 (sub-study 2) or the small molecule gamma secretase inhibitor nirogacestat (sub-study 3) in patients with relapsed/refractory multiple myeloma previously treated with ≥ 3 prior therapy lines which must have included ≥ 1 immunomodulatory agent, proteasome inhibitor, and anti-CD38 antibody [16].”
BackgroundFerron‐Brady, G., Rathi, C. D., Collins, J. W., Struemper, H., Opalinska, J., & Jewell, R. C. (2020) · Cancer Research · doi:10.1158/1538-7445.am2020-ct196 · Cited by 5
Cited by
Emerging new therapeutic antibody derivatives for cancer treatment
Jin, S., Sun, Y., Liang, X., Gu, X., Ning, J., Xu, Y., Chen, S., & Pan, L. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00868-x · Cited by 459
“Belantamab mafodotin (BLENREP®, GlaxoSmithKline) is a first-in-class antiBCMA ADC that was granted accelerated approval by the FDA in August 2020 as a monotherapy treatment for adult patients with RRMM who had received at least four prior therapies; belantamab mafodotin includes an anti-CD38 mAb, the proteasome inhibi…”
BackgroundAntibody–drug conjugates: Recent advances in linker chemistry
Su, Z., Xiao, D., Xie, F., Liu, L., Wang, Y., Fan, S., Zhou, X., & Li, S. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.03.042 · Cited by 403
Antibody–Drug Conjugates (ADCs): current and future biopharmaceuticals
Wang, R., Hu, B., Pan, Z., Mo, C., Zhao, X., Liu, G., Hou, P., Cui, Q., Xu, Z., Wang, W., et al. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01704-3 · Cited by 285
“Belantamab mafodotin was approved in early August 2020 by the FDA for the treatment of R/R MM in adult patients who have received at least four prior therapies [149].”
An Insight into FDA Approved Antibody-Drug Conjugates for Cancer Therapy
Tong, J. T. W., Harris, P. W. R., Brimble, M. A., & Kavianinia, I. (2021) · Molecules · doi:10.3390/molecules26195847 · Cited by 287
Linkers: An Assurance for Controlled Delivery of Antibody-Drug Conjugate
Sheyi, R., de la Torre, B. G., & Albericio, F. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14020396 · Cited by 224
Metadata
- Authors
- Markham, A.
- Affiliations
- Springer Nature (New Zealand) (NZ)
- Corresponding author
- Markham, Anthony
- Venue
- Drugs
- Published
- 2020-09-16
- Volume
- 80
- Issue
- 15
- Pages
- 1607-1613
- ISSN
- 0012-6667 (ISSN-L)
- 1179-1950
- OpenAlex
- W3087214205
- Semantic Scholar
- 1945dee187259a7acdf7846a96b2b6f238da2419
- Cited by
- 145
- References
- 7
- Citations by year
- 2026: 8 · 2025: 19 · 2024: 34 · 2023: 22 · 2022: 30 · 2021: 29 · 2020: 3
- FWCI
- 13.25
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Drugs (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Keywords
- belantamab mafodotin, antibody-drug conjugates, multiple myeloma, BCMA, monomethyl auristatin F, relapsed/refractory multiple myeloma, drug approval, microtubule inhibitors
- MeSH terms
- Progression-Free Survival, Adult, Animals, Clinical Trials as Topic, Humans, Infusions, Intravenous, Multiple Myeloma, Neoplasm Recurrence, Local, Neoplasm Staging, Oligopeptides, Drug Approval, Disease Progression, Immunoconjugates, Drug Resistance, Neoplasm, Xenograft Model Antitumor Assays, Cell Line, Tumor, Tubulin Modulators, B-Cell Maturation Antigen, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Belantamab Mafodotin: First Approval. https://app.cochat.ai/papers/10.1007/s40265-020-01404-x
- The paper
- Markham, A. (2020). Belantamab Mafodotin: First Approval. Drugs. https://doi.org/10.1007/s40265-020-01404-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.